PINK
NVSEF

Novartis AG

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Novartis AG Stock Price

Vitals

Today's Low:
$96.2
Today's High:
$96.2
Open Price:
$96.2
52W Low:
$70.0308
52W High:
$106.5
Prev. Close:
$99.5
Volume:
528

Company Statistics

Market Cap.:
$198.97 billion
Book Value:
25.068
Revenue TTM:
$53.07 billion
Operating Margin TTM:
27.69%
Gross Profit TTM:
$36.74 billion
Profit Margin:
14.41%
Return on Assets TTM:
7.86%
Return on Equity TTM:
13.32%

Company Profile

Novartis AG had its IPO on under the ticker symbol NVSEF.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Novartis AG has a staff strength of 103,000 employees.

Stock update

Shares of Novartis AG opened at $96.2 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $96.2 - $96.2, and closed at $96.2.

This is a -3.32% slip from the previous day's closing price.

A total volume of 528 shares were traded at the close of the day’s session.

In the last one week, shares of Novartis AG have slipped by -5.42%.

Novartis AG's Key Ratios

Novartis AG has a market cap of $198.97 billion, indicating a price to book ratio of 3.2152 and a price to sales ratio of 3.8151.

In the last 12-months Novartis AG’s revenue was $53.07 billion with a gross profit of $36.74 billion and an EBITDA of $20.03 billion. The EBITDA ratio measures Novartis AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Novartis AG’s operating margin was 27.69% while its return on assets stood at 7.86% with a return of equity of 13.32%.

In Q2, Novartis AG’s quarterly earnings growth was a positive 44.2% while revenue growth was a positive 6.5%.

Novartis AG’s PE and PEG Ratio

Forward PE
14.2857
Trailing PE
26.7222
PEG
5.6678

Its diluted EPS in the last 12-months stands at $3.6 per share while it has a forward price to earnings multiple of 14.2857 and a PEG multiple of 5.6678. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novartis AG’s profitability.

Novartis AG stock is trading at a EV to sales ratio of 3.9682 and a EV to EBITDA ratio of 6.6563. Its price to sales ratio in the trailing 12-months stood at 3.8151.

Novartis AG stock pays annual dividends of $3.461 per share, indicating a yield of 3.45% and a payout ratio of 51.22%.

Balance sheet and cash flow metrics

Total Assets
$110.98 billion
Total Liabilities
$31.91 billion
Operating Cash Flow
$0
Capital Expenditure
$996 million
Dividend Payout Ratio
51.22%

Novartis AG ended 2024 with $110.98 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $110.98 billion while shareholder equity stood at $51.85 billion.

Novartis AG ended 2024 with $0 in deferred long-term liabilities, $31.91 billion in other current liabilities, 842000000.00 in common stock, $0 in retained earnings and $29.52 billion in goodwill. Its cash balance stood at $10.89 billion and cash and short-term investments were $11.17 billion. The company’s total short-term debt was $8,536,000,000 while long-term debt stood at $18.26 billion.

Novartis AG’s total current assets stands at $33.49 billion while long-term investments were $2.43 billion and short-term investments were $289.00 million. Its net receivables were $9.54 billion compared to accounts payable of $5.35 billion and inventory worth $8.23 billion.

In 2024, Novartis AG's operating cash flow was $0 while its capital expenditure stood at $996 million.

Comparatively, Novartis AG paid $0.51 in dividends in 2024.

Other key metrics

Current Trading Price
$96.2
52-Week High
$106.5
52-Week Low
$70.0308
Analyst Target Price
$

Novartis AG stock is currently trading at $96.2 per share. It touched a 52-week high of $106.5 and a 52-week low of $106.5. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $101.15 and 200-day moving average was $91.95 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 394.7% of the company’s stock are held by insiders while 3607.8% are held by institutions.

Frequently Asked Questions About Novartis AG

The stock symbol (also called stock or share ticker) of Novartis AG is NVSEF

The IPO of Novartis AG took place on

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$167.54
-0.17
-0.1%
$0.08
-0.01
-14.68%
Beam Global (BEEMW)
$3.27
-0.03
-0.91%
$11.05
0.1
+0.91%
$930
-37.55
-3.88%
TCNS Clothing Co. Ltd (TCNSBRANDS)
$372.55
-14.5
-3.75%
$2.43
-0.46
-15.92%
$27.91
-0.22
-0.78%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Address

Lichtstrasse 35, Basel, Switzerland, 4056